The Investor Portal is administered by VP Securities A/S. VP Securities A/S is a Central Securities Depository (CSD) in Denmark authorised by the Danish Financial Supervisory Authority (Finanstilsynet) according to the Danish Securities Trading Act. Learn how VP Securities A/S process personal data.

For further information, please refer to our Notice of Personal Data Processing.

This also applies to notices to convene general meetings which will no longer be sent to shareholders as hardcopy by regular mail.

Shareholders are encouraged to sign up and register their email address via Novo Nordisk A/S’ InvestorPortal

Shareholders who wish to receive company information are responsible for ensuring that Novo Nordisk A/S is in possession of the correct email address and should sign up via the InvestorPortal. Learn more about how to sign-up your email.

Receipt of electronic communication from Novo Nordisk requires access to an email and a pdf-viewer.

Announcements of a general nature will be made available at novonordisk.com.

Holders of such certificates were thus encouraged to contact Danske Bank, Corporate Actions, via contact details below no later than 4 November 2018 in order to have their shareholdings registered and the physical certificates converted into registered shares in Novo Nordisk A/S and Novozymes A/S.

If the conversion was not completed by 4 November 2018, the corresponding shares have been sold pursuant to the Danish Companies Act. Holders of physical share certificates and interim certificates will be entitled to collect the net proceeds of the share sale within a period of three years following the sale.

See the announcement as published on Virk.dk for further information (in Danish).

The above applies to holders of physical share certificates and interim certificates in former Nordisk Gentofte A/S and Novo Industri A/S only and does not affect shareholders of registered shares in Novo Nordisk A/S.

Danske Bank, 3886 Corporate Actions,
Holmens Kanal 2-12, 1092 København K,
Telephone: (+45) 45 14 36 94
E-mail: corporate.actions@danskebank.dk

The total dividend for 2019 was DKK 8.35 for each A and B share, consisting of an interim dividend of DKK 3.00 (paid in August 2019) and a final dividend of DKK 5.35 (paid in March 2020) for each A and B share.

The interim dividend for 2020 of DKK 3.25 for each A and B share of DKK 0.20 was paid in August 2020.

The share buyback programme is a way for Novo Nordisk to return excess capital to the investors. By buying back shares and reducing the share capital, the value of the remaining outstanding shares increases.

The Annual General Meeting 2019 took place 21 March 2019.

The Annual General Meeting 2020 took place 26 March 2020.

You can look up and download historical share prices in the Shareholder tools section. You can also calculate the return on the investment you have made in Novo Nordisk shares

 

No – we will automatically get your new address.

 

ADR is an abbreviation for an American Depository Receipt. An ADR is a receipt for the shares of a foreign-based corporation held in the vault of a U.S. bank, entitling the shareholder to all dividends and capital gains.         

The depository bank responsible for Novo Nordisk’s ADR is JP Morgan and the contact information is:

J.P. Morgan
1 Chase Manhattan Plaza, Floor 58
New York, NY 10005
(866) JPM-ADRS (866 576-2377)
adr@jpmorgan.com

Q3 2020

SHARE Magazine UK |  SHARE Magazine DK

Index

  • Message from the CEO
  • Phase 2 trial successfully completed with ziltivekimab
  • Raised 2020 outlook on 8 October 2020
  • Not if, but how: new strategy steps up our efforts to Defeat Diabetes
  • 100% renewable power target for direct suppliers launched in 2020
  • 100 years ‎young: why we’re investing in the future of insulin
     

Q2 2020

SHARE Magazine UK |  SHARE Magazine DK

Index

  • Message from the CEO
  • Clinical results support Strategic Aspiration for obesity treatment
  • Novo Nordisk acquires Corvidia Therapeutics and expands presence in cardiovascular disease
  • Lose or reuse? How we are repurposing our insulin pens
  • A deep dive into NASH and Novo Nordisk’s activities in tackling this disease
  • Highlights from the first six months of 2020
     

Q1 2020

SHARE Magazine UK |  SHARE Magazine DK

Index

  • Message from the CEO
  • An unprecedented challenge: our response to COVID-19
  • Rybelsus® approved in the EU
  • Obesity through the lens: the truth from within
  • Prevention or cure? When it comes to type 1 diabetes, we are working on both
  • Highlights from the first three months of 2020

Q3 2019

SHARE Magazine UK |  SHARE Magazine DK

Index

  • Message from the CEO
  • A new era in diabetes care: Rybelsus® approved in the USA
  • New affordability initiatives to be launched in the USA
  • People and purpose: Monique Carter on driving culture change at Novo Nordisk
  • Intensifying China’s fight against diabetes
  • Highlights from the first six months of 2019

 

Q2 2019

SHARE Magazine UK |  SHARE Magazine DK

Index

  • Message from the CEO
  • A new mindset for environmental responsibility
  • Obesity: The brain is the battleground
  • Outcomes trials: Can semaglutide go even further in addressing patient needs?
  • Maximising the growth potential
  • Listen and lead: Ludovic Helfgott on returning biopharm to growth
  • Highlights from the first six months of 2019

 

Q1 2019

SHARE Magazine UK |  SHARE Magazine DK

Index

  • Message from the CEO
  • Oral semaglutide filed in the US and EU
  • The day I fired my doctor
  • Safely in the Rainbow
  • Shaped tablet key to oral delivery of insulin
  • Novo Nordisk addresses affordable insulin
  • Accelerating growth in Latin America
  • Highlights from the first three months of 2019

 

Q3 2018

SHARE Magazine UK |  SHARE Magazine DK

Index

  • Letter from the CEO, Lars Fruergaard Jørgensen
  • Highlights from the first nine months of 2018
  • Tresiba® revitalised with new ‘Hypos matter’ 
  • Novo Nordisk research centre opens in oxford
  • Connected insulin pens poised for launch

 

Q2 2018

SHARE Magazine UK | SHARE Magazine DK

Index

  • Letter from the CEO, Lars Fruergaard Jørgensen
  • Highlights from the first six months of 2018
  • Oral semaglutide shows promising results
  • Ozempic® heading for the European market
  • Novo Nordisk focuses on treating obesity
  • Red Cross and Novo Nordisk enters partnership

 

Q1 2018

SHARE Magazine UK

Index

  • Letter from the CEO, Lars Fruergaard Jørgensen
  • Highlights from the first three months of 2018
  • Oral semaglutide shows promising results
  • Ozempic® approved in the EU and Japan
  • First phase 3a trial with oral semaglutide completed
  • Updated Tresiba® label approved in the USA
  • How Novo Nordisk’s products in Cuba

Q3 2017

SHARE Magazine UK | SHARE Magazine DK

Index

  • Letter from the CEO, Lars Fruergaard Jørgensen
  • Highlights from the first nine months of 2017
  • Camilla Sylvest joins executive management
  • SUSTAIN 7: Semaglutide compared to dulaglutide
  • Victoza® CV label approved in the US and the EU
  • Fiasp® a fast-acting insulin approved in the US
  • Ambitious global goal: To prevent 100 million new cases of diabetes by 2045

 

Q2 2017

SHARE Magazine UK | SHARE Magazine DK

Index

  • Letter from the CEO, Lars Fruergaard Jørgensen
  • Highlights from the first six months of 2017
  • Label update for Tresiba® submitted in the US
  • A step closer towards a CV indication for Victoza®  
  • Phase 2 obesity data for semaglutide
  • New data on Xultophy® 
  • Why Novo Nordisk is helping refugees

 

Q1 2017

SHARE Magazine UK | SHARE Magazine DK

Index

  • Letter from the CEO, Lars Fruergaard Jørgensen
  • Highlights from the first three months of 2017
  • Doug Langa new head of North America Operations
  • Fiasp® launched in Canada and EU markets
  • New research centre in Oxford
  • CHMP endorses Refixia® 
  • World Diabetes Foundation 15 th anniversary

Investors

Share price

{{priceData.date}} {{priceData.time}}

{{priceData.currentPrice}} {{priceData.currency}}
Go to stock watch {{priceData.change}} {{priceData.currency}}

Annual Report

Cover page of the Novo Nordisk Annual Report 2020

Annual Report 2020

Download Annual Report